Related Experiment Video
Updated: Jul 5, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Paromomycin in the treatment of leishmaniasis
Shyam Sundar1, Jaya Chakravarty
1Banaras Hindu University, Institute of Medical Sciences, Department of Medicine, Varanasi-221005, India. drshyamsundar@hotmail.com
Background:
The treatment options for leishmaniasis are limited. Most of the drugs available need parenteral administration, are toxic, require monitoring and have a prolonged treatment duration. All these factors increase the cost of the treatment. The development of resistance to pentavalent antimonials in patients with visceral leishmaniasis in North Bihar, India, has added another dimension to the problem.
Objective:
To summarise the pharmacological and clinical data on antileishmanial activity of paromomycin and discuss the impact this agent may have on present treatment regimens.
Methods:
A literature search on paromomycin and leishmaniasis was done on PubMed and through Google.
Results:
Paromomycin, with its excellent efficacy, low cost, shorter duration of administration and good safety profile, has the potential to be used as a first-line drug.
More Related Videos
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
Anthelminthic Agents